ライフサイエンスコーパス: IgE

1 IgE activities were tested in basophil degranulation ass

2 IgE and IgG responses to 47 inhalant and food allergen c

3 IgE and IgG4 binding to sequential epitopes derived from

4 IgE antibodies are key mediators of antiparasitic immune

5 IgE binding was determined by ELISA.

6 IgE cross-linking inhibits critical virus-induced IFN-al

7 IgE production plays a crucial role in protective as wel

8 IgE reactivity to antigens from Gram-positive and Gram-n

9 IgE response was measured, and mechanistic parameters we

10 IgE to the extract and 12 molecules of D pteronyssinus w

11 IgE-anti-IL-24 showed acceptable predictive properties f

12 IgE-immunoblotting was also conducted using sera from ch

13 IgE-immunoblotting with peach leaf extract revealed in s

14 IgE-mediated FA was induced in BALB/c mice by oral gavag

15 IgE-mediated food allergy caused by jellyfish is rare wo

16 IgE-mediated food allergy status at 1 year was determine

17 IgE-western blot and IgE-ELISA were complemented by Skin

18 th specific IgE and challenged with Pen a 1 (IgE epitope valency of >/=8), although measurable respon

19 By using array analyses, more than 200 IgE autoantigens were found in patients with CSU that we

20 ulation was elicited when approximately 2700 IgE-FcepsilonRI complexes were occupied with specific Ig

21 temperature, behavioral effects, serum IL-4, IgE, and anti-drug Ab levels.

22 tifying the cellular origin of high affinity IgE and the clonal selection of high affinity memory B c

23 as allergic reaction, but how high affinity IgE antibodies are produced in memory responses is not c

24 1[EMR1](+)MPs), mast cell MPs (high-affinity IgE receptor [FcepsilonRI](+)c-kit(+)MPs), and basophil

25 tivation mediated through both high-affinity IgE receptors (FcepsilonRI) on mast cells and basophils

26 on mast cells and basophils and low-affinity IgE receptors (FcepsilonRII) on B cells.

27 FcepsilonRII-mediated signaling by allergen-IgE immune complexes increased IFN-gamma production in B

28 nt of serum inhibitory activity for allergen-IgE binding to B cells (IgE-facilitated allergen binding

29 mans and causes glycan-specific IgG and also IgE responses with clinical relevance.

30 ung inflammation, and IL-4, IL-5, IL-13, and IgE production.

31 rated a similar reduction in anaphylaxis and IgE.

32 IgE-western blot and IgE-ELISA were complemented by Skin Prick Testing (SPT)

33 hool eczema (PSE), FLG mutation, or both and IgE sensitization in childhood.

34 f IgG antithyroid AAbs (strong evidence) and IgE-anti-TPO (weak evidence) than controls.

35 rotease 1), increased serum IgG1 anti-EW and IgE levels, and increased IL-4 and IL-13 secretion after

36 hils (n=60) to specific anti-FcepsilonRI and IgE-independent fMLP stimulation was determined by basop

37 contribute to germinal center formation and IgE switching in type 2 immunity.

38 n a marked reduction in TFH cell numbers and IgE antibody levels, but type 2 cytokine responses and e

39 pes were defined by using questionnaires and IgE measures at the ages of 8 and 16 years.

40 ions between prevalent asthma, rhinitis, and IgE sensitization and mold or dampness indicators were a

41 Anti-IgE mAb has positive effects in OA induced by persulfate

42 Anti-IgE-treated mice showed a significant improvement in ast

43 We demonstrated that these low-affinity anti-IgE mAbs bind to the cell surface-bound IgE without trig

44 were also significantly decreased after anti-IgE administration 24 hour and 48 hour after the last AP

45 Omalizumab, an anti-IgE antibody, is used to treat patients with severe alle

46 Omalizumab, an anti-IgE mAb, is the first targeted biologic therapeutic appr

47 ared possible because both antigens and anti-IgE dissociated rapidly from cells after washing to remo

48 rom isolated basophils following either anti-IgE, IL-3 or fMLP stimulation.

49 ical analysis of the lung sections from anti-IgE-treated mice revealed normal inflammatory patterns s

50 ns that relate to the increasing use of anti-IgE mAbs for the treatment of allergic disease.

51 cium/magnesium was added at the time of anti-IgE stimulation.

52 The efficacy of omalizumab (anti-IgE) and increased IgE levels in patients with chronic s

53 od was incubated with peanut extract or anti-IgE and tests were performed as follows: BAT-CD63 upregu

54 ore, we demonstrated that a therapeutic anti-IgE antibody, omalizumab, which inhibits IgE binding to

55 We did a pilot study testing whether anti-IgE (omalizumab) combined with multifood oral immunother

56 ls were injected intraperitoneally with anti-IgE mAb or PBS 6 hours before challenge with AP or salin

57 Mice were subsequently treated with anti-IgE, and the symptoms of passive IgE-mediated anaphylaxi

58 II) expression and surface bound antibodies (IgE, IgG) were quantified on basophils.

59 The antibody IgE plays a central role in allergic disease mechanisms.

60 As IgE glyco-epitopes, also referred to as cross-reactive c

61 surface plasmon resonance, were recloned as IgE and antigen-binding fragments.

62 An alpha-Gal-associated IgE cross-reactivity profile (IgE against CTX, Bos d TG,

63 d the ratio of on treatment IgE and baseline IgE levels.

64 tients with CSU are linked to their baseline IgE levels, their IgE levels after omalizumab treatment,

65 Interestingly, differences between IgE and IgG4 binding intensity to CM peptides decreased

66 c antibody, inhibits the interaction between IgE and FcRI, preventing mast cell and basophil activati

67 ication resulted in a protein unable to bind IgE from allergic patients.

68 ast cell and basophil activation, and blocks IgE binding to CD23 on B cells and antigen-presenting ce

69 ctively), and clinically relevant cell-bound IgE (67.3 days).

70 to and cross-link the cells' receptor-bound IgE antibodies.

71 ic reactivity by targeting the surface-bound IgE of the allergic effector cells via low-affinity anti

72 anti-IgE mAbs bind to the cell surface-bound IgE without triggering anaphylactic degranulation even a

73 , and the pathogenic relevance of anti-BP180 IgE has been suggested in various experimental models an

74 Assaying for anti-BP180 IgE increased the diagnostic sensitivity by only 2.2% (1

75 he diagnostic importance of serum anti-BP180 IgE.

76 d against CCDs was investigated by bromelain IgE inhibition and concanavalin A binding assays using s

77 allergen by the immune system, especially by IgE antibodies, is prevented.

78 ens in patients with high levels of anti-CCD IgE antibodies.

79 Our results provide a new model for the CD23-IgE interaction.

80 e we present the crystal structure of a CD23/IgE-Fc complex and conduct isothermal titration calorime

81 ctivity for allergen-IgE binding to B cells (IgE-facilitated allergen binding).

82 this study, we identified and characterized IgE-binding proteins from the mosquito species Aedes aeg

83 of-concept studies of a mouse/human chimeric IgE antibody (MOv18 IgE), which is specific for the canc

84 Clinically, IgE-anti-IL-24 levels showed an association with disease

85 Among students with current IgE-mediated food allergy, those with resolved or curren

86 tigen-specific germinal centers (23.3 days), IgE(+) and IgG1(+) PCs (60 and 234.4 days, respectively)

87 Genetic depletion of Tfh cells decreased IgE antibody levels and protected mice from anaphylaxis,

88 is specifically relevant for IL-4-dependent IgE responses to allergens with the amount of IL-4 produ

89 allergens, hydrolase activity and detectable IgE/IgG reactivity are strongly correlated, while no pro

90 are required to test the impact of different IgE molecular profiles on AIT response.

91 ar cues, including antigen-immunoglobulin E (IgE) complexes, bacteria, viruses, cytokines, hormones,

92 sensitization, serum total immunoglobulin E (IgE), forced expiratory volume in one-second (FEV1) and

93 s for determining the immunogenicity of each IgE binding epitope.

94 Early IgE sensitization onset, parental hay fever, and higher

95 ylactic reactions by essentially eliminating IgE-mediated activation of mast cells.

96 munoblots were made in parallel to elucidate IgE and IgG reactivity, and putative function analyses w

97 Post-AIT sera exerted IgE-blocking activity.

98 ent an enzyme-linked immunosorbent assay for IgE antibodies against the 16th noncollagenous domain of

99 and application of internal calibrations for IgE and IgG4 were assessed.

100 asthmatic subjects have lower cut points for IgE levels (268 IU), fraction of exhaled nitric oxide va

101 tria, were tested in ImmunoCAP ISAC((R)) for IgE reactivity to 112 single allergens.

102 confirming that eosinophils are required for IgE-mediated tissue injury.

103 127 controls undergoing allergy testing for IgE levels, and 30 controls with pemphigus vulgaris or p

104 Free IgE-Fc adopts an acutely bent structure, but in the comp

105 lizumab binds to free IgE, which lowers free IgE levels and causes FcepsilonRI receptors on basophils

106 Omalizumab binds to free IgE, which lowers free IgE levels and causes FcepsilonRI

107 t in comparison with patients suffering from IgE-mediated allergic rhinitis (n=10) and healthy contro

108 Furthermore, IgE autoantibodies fail to induce BP in eosinophil-defic

109 apacity of tonsil B-cell subsets to generate IgE(+) PCs and the class switching pathways involved.

110 -PCR, we examined the phenotype of generated IgE(+) cells, the capacity of tonsil B-cell subsets to g

111 tions regarding the relevance of anti-glycan IgE for allergic diseases.

112 lls/ILC2 cells, IgG, and FcRgamma>mast cells>IgE and FcepsilonRI>basophils.

113 naphylaxis (IA), six (9%) were found to have IgE to alpha-gal.

114 atitis, colitis, hypereosinophilia, and high IgE levels.

115 .02 or 03 isoforms, Amb a 1.01 showed higher IgE-binding activity.

116 fiber-based fluorometric method; passive HR-IgE-stripped donor basophils were incubated with partici

117 By using a human IgE mAb, the corresponding allergen Bet v 1, and a panel

118 c effector cells via low-affinity anti-human IgE Abs with dissociation constants in the 10(-6) to 10(

119 haracterize the development pathway of human IgE(+) PCs and to determine the ontogeny of human IgE(+)

120 ) PCs and to determine the ontogeny of human IgE(+) PCs.

121 IgG4, IgE, and cell-specific signatures are regulated in patie

122 neous reactions (P = .022) and enhanced IgG4/IgE ratios (P = .012).

123 To address immunological IgE cross-reactivity on molecular level, seven recombina

124 unction of subsets of IgG1 memory B cells in IgE production and find that two subsets of IgG1 memory

125 icant (P < .001) dose-dependent reduction in IgE allergen binding across all treatment groups (70 mug

126 e (BTK) is an emerging therapeutic target in IgE receptor (IgER)-cross-linked basophils.

127 e and humoral immune responses that included IgE-dependent basophil activation and measurement of ser

128 derived from a subset of proteins (including IgE, Bank1, chondroitin sulfate synthase 2, Cmip, and Ft

129 icacy of omalizumab (anti-IgE) and increased IgE levels in patients with chronic spontaneous urticari

130 produce cytokines, express CD154, and induce IgE production by autologous B cells.

131 locking IgG/IgG4 antibodies that can inhibit IgE-dependent activation mediated through both high-affi

132 era were tested for their ability to inhibit IgE recognition of Cyp c 1, Cyp c 1-specific basophil de

133 s IgE binding to FcepsilonRI, also inhibited IgE binding to CD23.

134 nti-IgE antibody, omalizumab, which inhibits IgE binding to FcepsilonRI, also inhibited IgE binding t

135 , as well as borderline association with low IgE reactivity to any allergen.

136 ace expression of the short form of membrane IgE (mIgES ), which is homologous to mouse mIgE, and the

137 f a mouse/human chimeric IgE antibody (MOv18 IgE), which is specific for the cancer-associated antige

138 is clear if the antitumor activity of MOv18 IgE in these preclinical experiments can be replicated i

139 gh no association of circulating BP180 NC16A IgE antibodies with urticarial or erythematous lesions w

140 te the allergic immune response toward a non-IgE condition.

141 Analysis of IgE reactivity revealed that ten of thirteen patients we

142 The potential clinical application of IgE-derived drugs in clinical oncology is clear if the a

143 of this study was to evaluate the binding of IgE to five recombinant beta-conglutin isoforms (rbeta)

144 arge pediatric population, the complexity of IgE sensitization profiles against P. pratense molecules

145 Ag-mediated crosslinking of IgE-FcepsilonRI complexes activates mast cells and basop

146 The unique differentiation of IgE cells suggests unconventional mechanisms of IgE memo

147 PC differentiation of IgE(+) cells is accompanied by the down-regulation of su

148 , greater intensity and broader diversity of IgE and IgG4 binding have been found in children with pe

149 above foods prior to age 3 with evidence of IgE sensitization.

150 igate this question, we compared the fate of IgE-ICs in human B cells and in CD23-expressing monocyte

151 of bacteria responsible for the induction of IgE sensitization to microbial antigens.

152 new pathway for therapeutic intervention of IgE-mediated reactions.

153 We then analyzed serum levels of IgE antibody and challenged mice with peanut proteins.

154 Finally, we determined the levels of IgE specific for staple foods and house dust mite allerg

155 e existing literature about the half-life of IgE in both the circulation and skin.

156 cells suggests unconventional mechanisms of IgE memory.

157 he requirement for CCL7 in a murine model of IgE-mediated allergic conjunctivitis.

158 On the other hand, the persistence of IgE blocking antibody 1 year after discontinuation might

159 blots demonstrating a slight predominance of IgE reactivity to SPP compared to TOT and APE.

160 The presence of IgE autoantibodies against the transmembrane protein BP

161 une-blotted HDM extract, and the presence of IgE-reactive antigens in HDM was demonstrated by qualita

162 associated with the increased prevalence of IgE reactivity to cypress pollen extracts because of CCD

163 In addition, NMBA sales and prevalence of IgE sensitization to PHO and SUX among 'allergics' were

164 cells supported the sustained production of IgE antibody in vivo in the absence of other T-cell subs

165 xpress CD154 and stimulate the production of IgE by B lymphocytes through IL-25/IL-33 stimulation or

166 ELISA was used to assess the production of IgE, type 2 cytokines, and Ccl24.

167 The reactivity of IgE antibody to the extracted protein did not differ amo

168 ing to CD23 is involved in the regulation of IgE synthesis and allergen transcytosis.

169 signal weakness contributes to restraint of IgE B cell responses.

170 n from age 4 to 6 months reduces the risk of IgE-mediated egg allergy in infants with hereditary risk

171 The extreme sparsity of IgE(+) cells in vivo has confined their study almost ent

172 ion for both the prevention and treatment of IgE-mediated food allergies.

173 rutinib, dasatinib, AVL-292, and CNX-774) on IgE-dependent activation and histamine release in blood

174 previously reported effects of TGF-beta1 on IgE-mediated activation, demonstrate that TGF-beta1 can

175 ion by lymph node cells but had no effect on IgE production.

176 up study on the effects of PHO withdrawal on IgE sensitization and anaphylaxis reporting.

177 rst known ingestion with typical rapid onset IgE-mediated symptoms.

178 y increases the risk of asthma, rhinitis, or IgE sensitization in children followed from birth to 16

179 d with anti-IgE, and the symptoms of passive IgE-mediated anaphylaxis, MC activation, Ca(2+) -mobiliz

180 the repertoires of high affinity pathogenic IgE and low affinity non-pathogenic IgE.

181 thogenic IgE and low affinity non-pathogenic IgE.

182 us of Bet v 1 inhibited binding of patients' IgE antibodies to Bet v 1.

183 ally enhancing BCR signal strength permitted IgE(+) memory B cells-which essentially do not exist und

184 ion of allergen-specific IgE revealed plasma IgE from DOCK8-deficient patients is directed against st

185 T or elevated allergen-specific serum/plasma IgE levels.

186 were associated with a broader polymolecular IgE sensitization pattern.

187 d reactions to foods, 48.1% were potentially IgE-mediated (affecting 50.8% of food allergy or intoler

188 Gal-associated IgE cross-reactivity profile (IgE against CTX, Bos d TG, and HSA-alpha-Gal) was identi

189 S comparing 73 infants with challenge-proven IgE-mediated peanut allergy against 148 non-allergic inf

190 om human mast cells sensitized with purified IgE of patients with CSU but not control subjects.

191 demonstrated by qualitative and quantitative IgE inhibition experiments.

192 mulated human B cells, 9cRA markedly reduced IgE production and enhanced IgA production.

193 ed to engineer allergen mutants with reduced IgE Ab binding for immunotherapy.

194 SPT) to birch pollen were analyzed regarding IgE to major birch and grass pollen allergens Bet v 1 an

195 The VDR directly and indirectly regulates IgE production in B cells.

196 tibody production in memory B cell responses.IgE is an important mediator of protective immunity as w

197 Some patient sera revealed IgE-binding proteins matching LTP and/or profilin.

198 kDa) reacted specifically with the patient's IgE.

199 perantigens to framework regions of anti-SEE IgE in anti-SEE IgE-FcepsilonRI complexes.

200 ramework regions of anti-SEE IgE in anti-SEE IgE-FcepsilonRI complexes.

201 also influenced by asthma control and serum IgE levels, whereas Emax values were related to 24-hour

202 IV-infected youth with current asthma, serum IgE levels were inversely correlated with CD8 T-cell cou

203 was observed in subjects with elevated serum IgE and airway eosinophilia.

204 asthma, atopic dermatitis, or elevated serum IgE levels, using Mendelian randomization (MR) methodolo

205 ere able to block the binding of human serum IgE.

206 69 women and 48 men), anti-BP180 NC16A serum IgE was detected in 47 (40.2%) and correlated with disea

207 id de facto nonreactive with patients' serum IgE.

208 the negative control), a food-specific serum IgE concentration of more than 4 kU/L for each food, or

209 ation to hen's egg (increased specific serum IgE levels) by age 12 months.

210 dministered, number of reactions where serum IgE antibodies (>/=0.35 kUA /l) to suxamethonium (SUX) a

211 ng with the binding sites of patients' serum IgEs.

212 itor imatinib protected the mice from severe IgE-mediated anaphylaxis.

213 Development of severe IgE-mediated hypovolemia and shock required VE-restricte

214 dies, sensitization-induced IgG did not show IgE-blocking activity.

215 he population aged 12-21 years, 53.5% showed IgE reactivity to at least one allergen tested.

216 cal presentation and evidence of nut specifc IgE shown by a positive skin prick test (SPT) or specifi

217 Probability curves for Ana o 3-specific IgE have been calculated, and a 95% probability could be

218 years to assess eczema and allergen-specific IgE (sIgE) and perform skin prick testing (SPT).

219 ltaneous detection of food allergen-specific IgE and IgG4 , and compared it with ImmunoCAP and Immuno

220 Allergen-specific IgE antibodies are a hallmark of type I allergy.

221 on the levels of total and allergen-specific IgE in patients with birch pollen allergy.

222 Examination of allergen-specific IgE revealed plasma IgE from DOCK8-deficient patients is

223 Binding of allergen-specific IgE to its high-affinity receptor FcepsilonRI on basophi

224 Total and allergen-specific IgE, IgG and basophil sensitivity were measured before a

225 induces rises of systemic allergen-specific IgE, we performed a double-blind placebo-controlled pilo

226 tokine responses and serum allergen-specific IgE/IgG1 levels.

227 , serum levels of specific IgG4 and specific IgE and safety were also evaluated.

228 ly associated with parental BHR and specific IgE measured before conception than after birth [BHR: aR

229 ck test (SPT) for Citrus unshiu and specific IgE test for orange and grapefruit were positive.

230 re, spirometry, skin prick test and specific IgE were evaluated yearly.

231 lium; and the production of antigen-specific IgE and IgG1 in serum.

232 e levels, basophil numbers, antigen-specific IgE, cytokine levels, and IL-4, INF-gamma and Foxp3 gene

233 ed infants, 23 (5.7%) had hen's egg-specific IgE before randomization.

234 associated with concurrent elevated specific IgE against any allergen [adjusted OR (aOR) = 1.40; 95%

235 alpha-Gal-specific IgE Ab cause a special form of meat allergy characterize

236 alpha-Gal-specific IgE was determined by ImmunoCAP.

237 ew the effect of glycans and glycan-specific IgE on sensitization to allergens and allergy diagnosis

238 live/ash pollen, house dust mites), specific IgE did not show marked differences between regions and

239 The presence of specific IgE directed against CCDs was investigated by bromelain

240 a positive skin prick test (SPT) or specific IgE (sIgE) test.

241 of polysensitization, but no other specific IgE sensitization patterns were found.

242 -/-) mice induced low titers of OVA-specific IgE compared to the WT-OVA/alum model.

243 Peanut-specific IgE levels significantly declined in E-OIT-treated child

244 ndard-care controls, in whom peanut-specific IgE levels significantly increased (relative risk, 19.42

245 Total IgE, grass pollen-specific IgE, and skin prick test reactivity to grass pollen were

246 apy increased serum Phleum pratense-specific IgE levels (P = .001) compared with those in the control

247 vironmental antigens based on serum specific IgE levels at age 3 years in high-risk children.

248 gories, appropriate use of testing (specific IgE measurement, skin prick tests, and oral food challen

249 itic anhydride (TMA) can elicit TMA-specific IgE (sIgE), which may lead to occupational asthma (OA).

250 omponent-resolved diagnostics using specific IgE to 2 S albumins has shown to be a valuable new optio

251 ilonRI complexes were occupied with specific IgE and challenged with Pen a 1 (IgE epitope valency of

252 ms in samples from 20 patients with specific IgE antibodies to alpha-gal and 10 controls.

253 ma symptom severity, BHR, total and specific IgEs from 1991 to 1993, and data on 9100 offspring born

254 nd 1.40 (1.03, 1.91), respectively; specific IgEs: 3.08 (2.13, 4.45) and 1.83 (1.45, 2.31), respectiv

255 en-presenting cells and we aimed at studying IgE-dependent antigen presentation in both cell types.

256 formatics pathway analysis demonstrated that IgE activation aligned with processes such as oxidative

257 brutinib was confirmed by demonstrating that IgE-dependent histamine release in ex vivo blood basophi

258 nding became blurred with the discovery that IgE antibodies were the effector molecules of the allerg

259 The IgE-blocking activity of post-AIT sera was assessed in v

260 HHP treatment decreased the IgE and IgG-binding capacities, indicating a significant

261 and mediator release assay to determine the IgE cross-linking capability of treated and untreated sa

262 ng tools, but allergen molecules dissect the IgE response on a molecular level and put allergy resear

263 On the other hand, the IgE-binding glycan allergen galactose-alpha-(1,3)-galact

264 rately induced a measurable reduction in the IgE binding properties of pastes made from treated cashe

265 sting that each protein component masked the IgE-reactive epitopes in the other protein component mor

266 The evolution of the IgE response to the numerous allergen molecules of Derma

267 imed at analyzing the characteristics of the IgE sensitization to Phleum pratense molecules and inves

268 the allergic immune response by reducing the IgE response but promoting the IgA response.

269 long-lived memory B cells that replenish the IgE(+) PC compartment.

270 The results showed that the IgE reactivity of protein components in heterologous pol

271 e linked to their baseline IgE levels, their IgE levels after omalizumab treatment, and the ratio of

272 While HMW agents act mainly through IgE-mediated mechanisms, LMW agents appear to act throug

273 ly 38% of multimorbidity was attributable to IgE sensitization.

274 as diagnosed with a jellyfish allergy due to IgE mediated anaphylaxis after ingestion.

275 sion and leads to desensitization of mice to IgE-mediated reactions.

276 e to the threshold required for switching to IgE production.

277 Total IgE, grass pollen-specific IgE, and skin prick test reac

278 enome-wide DNA methylation in WBCs and total IgE levels in 2 studies of Hispanic children: the Puerto

279 up, younger age at recruitment, higher total IgE, higher blood eosinophil percentage and number, and

280 ntic treatment reduces STH prevalence, total IgE, and eosinophil count but has no effect on IR at the

281 e initial visit to our hospital, serum total IgE level was 545IU/ml.

282 nt was also negatively associated with total IgE (adjusted geometric mean ratio 0.94 [0.88 to 0.99]).

283 umber of CD23(+) cells correlated with total IgE levels (RS = 0.53, P = .03) and allergen-induced ski

284 al-sIgE positivity was associated with total IgE levels and recent tick bites.

285 ts, were significantly associated with total IgE levels.

286 mab treatment, and the ratio of on treatment IgE and baseline IgE levels.

287 understanding of basic mechanisms underlying IgE-mediated food allergies and novel therapeutic approa

288 d using transglutaminase, and their in vitro IgE reactivity and digestibility under simulated gastro-

289 ization and the inflammatory response, while IgE binding to CD23 is involved in the regulation of IgE

290 ,3)-galactose (alpha-Gal) is associated with IgE-mediated delayed anaphylaxis in meat allergy.

291 Children with IgE-mediated CMA were randomly allocated to the EHCF or

292 noCAP and ImmunoCAP ISAC and correlated with IgE- and IgG4 -specific fluorescence on silicon microarr

293 uals, and investigate their correlation with IgE/IgG responses and protein function.

294 ine-releasing factor (HRF) interactions with IgE and food allergy in a murine model.

295 kinetics based on FcepsilonRI occupancy with IgE and allergen dose.

296 immunotherapy is effective in patients with IgE-dependent allergic rhinitis and asthma.

297 The molecule is also reactive with IgE from sera of maize-allergic subjects.

298 n total reports (P < 0.001) and reports with IgE antibodies to PHO (P = 0.008) and SUX (P = 0.001) at

299 Our data demonstrate that post-AIT sera with IgE-blocking activity ameliorate allergic airway inflamm

300 For mast cells treated with IgE and Ag, the presence of CCL7 synergistically enhance